Ronald Tomlinson
AstraZeneca (United States)(US)Covance (United States)(US)
Publications by Year
Research Areas
Neuroscience and Neuropharmacology Research, Cancer-related Molecular Pathways, Wnt/β-catenin signaling in development and cancer, Ubiquitin and proteasome pathways, Protein Degradation and Inhibitors
Most-Cited Works
- → Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling(2009)2,068 cited
- → PIKfyve, a Class III PI Kinase, Is the Target of the Small Molecular IL-12/IL-23 Inhibitor Apilimod and a Player in Toll-like Receptor Signaling(2013)219 cited
- → EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex(2019)194 cited
- → Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA)(2018)131 cited
- → Identification of NVP-TNKS656: The Use of Structure–Efficiency Relationships To Generate a Highly Potent, Selective, and Orally Active Tankyrase Inhibitor(2013)122 cited
- → Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers(2018)120 cited
- → Structure‐Based Design of Selective Noncovalent CDK12 Inhibitors(2017)52 cited
- → Enzyme-Activated Antagonists of the Strychnine-Insensitive Glycine/NMDA Receptor(1994)44 cited
- → One-Pot C–N/C–C Cross-Coupling of Methyliminodiacetic Acid Boronyl Arenes Enabled by Protective Enolization(2012)35 cited
- → The magnetic susceptibility of some semicarbazones, oximes and 2:4-dinitrophenylhydrazones(1959)31 cited